Author + information
- Received December 8, 2014
- Revision received December 30, 2014
- Accepted January 6, 2015
- Published online March 1, 2015.
- ∗NYP Columbia Heart Valve Center, Columbia University Medical Center, New York, New York
- †New York Presbyterian Hospital, New York, New York
- ‡Department of Cardiovascular Medicine, Morristown Medical Center/Atlantic Health Systems, Morristown, New Jersey
- §Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas
- ↵∗Reprint requests and correspondence:
Dr. Rebecca T. Hahn, Columbia University Medical Center, 622 West 168th Street, PH3-342, New York, New York 10032.
Transcatheter aortic valve replacement (TAVR) with the use of the self-expandable Revalving system is an accepted alternative to surgical replacement for severe, symptomatic aortic stenosis in high-risk or inoperable patients. Intraprocedural imaging relies on fluoroscopic guidance, with echocardiographic imaging used as a supportive imaging modality. Intraprocedural transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) offer real-time imaging guidance throughout the procedure and may contribute to improving procedural results. Registries suggest that TAVR may be performed in lower-surgical-risk patients with equal outcomes to high-risk patients with ongoing randomized trials comparing these results with surgical outcomes. Understanding the utility of echocardiographic imaging in diagnosing or preventing complications may be particularly important as we move toward these lower-risk patient populations. This imaging compendium is intended to be a comprehensive compilation of intraprocedural complications imaged by intraprocedural echocardiography.
Dr. Hahn has Core Lab contracts with Edwards Lifesciences for which she receives no direct compensation; and is a speaker for Philips Healthcare, St. Jude Medical, and Boston Scientific. Dr. Gillam’s Core Lab has contracts with Medtronic and Edwards Lifesciences (for which she receives no direct compensation). Dr. Little is a co-investigator for the CoreValve Pivotal Extreme Risk and High Risk Clinical Trials; and has received research support from St. Jude Medical and Medtronic Structural Heart.
- Received December 8, 2014.
- Revision received December 30, 2014.
- Accepted January 6, 2015.
- American College of Cardiology Foundation